跳至主要内容
临床试验/NCT03085043
NCT03085043
进行中(未招募)
不适用

Magnetic Resonance Imaging as a Comprehensive Staging Tool for the Evaluation of High-Risk Prostate Carcinoma

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 98 人2016年4月20日

概览

阶段
不适用
干预措施
Bone Scan
疾病 / 适应症
Prostate Carcinoma
发起方
M.D. Anderson Cancer Center
入组人数
98
试验地点
1
主要终点
Accuracy of whole body magnetic resonance imaging (MRI)
状态
进行中(未招募)
最后更新
上个月

概览

简要总结

This trial studies how well magnetic resonance whole body diffusion-weighted imaging works in finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with high-risk prostate cancer. Diagnostic procedures, such as magnetic resonance whole body diffusion-weighted imaging (a method to show how water moves in a certain area) may help find bone or lymph nodes metastasis.

详细描述

PRIMARY OBJECTIVES: I. To compare accuracies of whole body magnetic resonance imaging (MRI) versus bone scan plus computed tomography (CT) scan in detecting bone or lymph node metastasis in high risk prostate cancer patients. OUTLINE: Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance whole body (WB)-diffusion-weighted imaging (DWI) over 20-30 minutes.

注册库
clinicaltrials.gov
开始日期
2016年4月20日
结束日期
2026年4月30日
最后更新
上个月
研究类型
Interventional
研究设计
Single Group
性别
Male

研究者

责任方
Sponsor

入排标准

入选标准

  • Prostate carcinoma patients at high risk for metastasis with prostate-specific antigen (PSA) more than 20 ng/ml and/or Gleason score = 8/ \>
  • Ability to understand and sign informed consent.

排除标准

  • Patient is at low risk for metastasis with Gleason score at diagnosis \<
  • Currently receiving or history of systemic therapy with testosterone suppressing medication (i.e., lupron, degarelix, abiraterone, enzalutamide) or local radiation therapy.
  • Contraindication to magnetic resonance imaging (MRI).

研究组 & 干预措施

Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)

Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.

干预措施: Bone Scan

Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)

Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.

干预措施: Computed Tomography

Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)

Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.

干预措施: Magnetic Resonance Imaging

Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)

Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.

干预措施: Magnetic Resonance Whole Body Diffusion-Weighted Imaging

结局指标

主要结局

Accuracy of whole body magnetic resonance imaging (MRI)

时间窗: Up to 6 months

Accuracy will be estimated along with 95% confidence intervals for whole body MRI (for bone and lymph node metastasis), bone scan (for bone metastasis), and computed tomography (CT) scan (for lymph node metastasis). Comparisons between modalities will be performed using McNemar's test. Other statistical analyses will be carried out as appropriate.

次要结局

  • Sensitivity of MRI, bone scan, and CT scan(Up to 9 years)
  • Positive predictive value (PPV) of MRI, bone scan, and CT scan(Up to 9 years)
  • Negative predictive value (NPV) of MRI, bone scan, and CT scan(Up to 9 years)
  • Detection of other types of metastases(Up to 9 years)
  • Specificity of MRI, bone scan, and CT scan(Up to 9 years)

研究点 (1)

Loading locations...

相似试验